Quite a few brokerages have predicted that the stocks of PFE will be putting up a quarterly sum of $17.54 billion for the current quarter. According to a report, three of the analysts have already provided estimates into the earnings of the company.
The ball has been rolled from a sum of $16.82 billion, with the highest coming in at $18.50 billion. The company did put up a sales sum of $11.80 billion the previous year, but that indicates an annual growth rate of about 48.6%. The company will be reporting its next quarterly report on the 28th of July.
The Quarterly Report Of PFE
PFE did previously report their quarterly earnings on the 4th of May. The biopharmaceutical company did report an EPS of $0.93 for the quarter, which was more than the consensus estimate of $0.78. The return on equity for the company was 24.55%, with a net margin of around 22.09%. The revenue generated by the company during this period was $14.58 billion, which is more than the consensus estimate of $13.41 billion.
There have been quite a few research equities that have commented on the stocks of PFE. Morgan Stanley has already increased the price target of the company from $38 to $42 with a rating of equal weight in a 10th May research report. The Goldman Sachs Group has also put up a price target of $45 with a price rating of neutral in a 24th May research report.
Mizuho Securities has also put up a rating of neutral with a price target of $42 in a 12th May research report. TheStreet has gone ahead and issued the company a rating of c+ to b- in a 3rd May research report. JPMorgan Chase & Co has also issued the company with a rating of neutral along with a price target of $40.
Currently, twelve investment analysts have issued the company stocks with a rating of hold, while two others have put up a rating of buy. PFE has a hold consensus rating with a $41.36 price target.
